Davita Inc vs Ulta Beauty Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Ulta Beauty Inc trades at $562.39 (market cap $23.32B). The key difference: Ulta Beauty Inc is far larger — about 2.1× Davita Inc's market cap, and Davita Inc is more actively traded (650,294 versus 321,683). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Ulta Beauty Inc for 92 Days on average.
| DVA | ULTA | |
|---|---|---|
Market Cap | $11.28B | $23.32B |
Volume | 650,294 | 321,683 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $706.82 |
52-Week Low | $103.87 | $450.75 |
Typical Hold Time | 113 Days | 92 Days |
Enterprise Value | $24.00B | $25.63B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
ULTA trades at $564.21, up 3.09% today, with a bullish technical outlook and strong analyst support. The stock has shown robust earnings beats in recent quarters, with Q1 and Q2 2026 exceeding expectations, and the company raised its 2026 guidance. Revenue growth is steady, though net margins have softened slightly from 12.17% in 2023 to 10.63% in 2025. Valuation ratios like a P/E of 19.86 and P/S of 1.86 appear reasonable relative to profitability metrics such as a 46.12% ROE.
The investment case hinges on execution of raised guidance and e-commerce momentum, but risks include margin pressure and flat store traffic. With a consensus price target of $624.93 implying ~11% upside and no sell ratings from analysts, the stock presents a growth opportunity tempered by near-term consumer and competitive challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →